The International Tennis Integrity Agency (ITIA) confirms that Kamil Majchrzak, a 26-year-old Polish tennis player, has been provisionally suspended under Article 7.12.1 of the 2022 Tennis Anti-Doping Programme (TADP). The ITIA sent the player a pre-Charge Notice of an Anti-Doping Rule Violation on 30 November 2022 under Article 2.1 of the Programme (presence of a Prohibited Substance in a Player’s Sample) and/or Article 2.2 (Use of a Prohibited Substance without a valid TUE).
Majchrzak, who had an ATP ranking of 78 at the time of being tested, provided samples whilst competing at three events – the Sofia Open in September, Japan Open in October and the FILA Open Seoul Challenger in October. The samples from each of these tests were split into A and B samples and the subsequent analysis of the A samples found that:
- One sample contained SARM S-22 and a metabolite of LGD-4033
- Two samples contained SARM S-22 and metabolites of a PPARδ agonist
SARM S-22, LGD-4033 and PPARδ agonists are all non-Specified substances listed in the 2022 World Anti-Doping Agency (WADA) Prohibited List. Adverse Analytical Findings for non-Specified Substances carry a mandatory provisional suspension.
The player has the right to request that the B samples are analysed to see if they confirm the A sample findings. While provisionally suspended, he is ineligible to compete in or attend any sanctioned tennis events organised by the governing bodies of the sport.
The ITIA is the delegated third party, under the World Anti-Doping Code of the International Tennis Federation, the international governing body for the sport of tennis and signatory of the Code. The ITIA is responsible for the management and administration of anti-doping across professional tennis in accordance with the 2022 TADP.
Ends
Published 09 December 2022 11:30
